The FDA cleared a second arm for enrollment in the trial after one NSCLC patient demonstrated a complete response to the non-boosted therapy.

Researchers hope to undertake clinical studies in multiple cancers, including ovarian cancer, glioblastoma, and others.

For more than a decade, CAR-T therapy has been the miracle of oncology, turning end-stage blood cancers into curable diseases ...

Experts at Cincinnati Children's report proof-of-concept results that may sharply reduce the risk of a lethal side effect that has negatively impacted the ...

For many people diagnosed with cancer, treatment with immune checkpoint inhibitors (ICIs) has dramatically extended lives.

The difficulty is that EBV lives latently in B cells in the blood at a frequency, in most immunocompetent individuals, of about 1 in 100,000 to 1 in a million. That level of infection is below the ...

Today, the American Diabetes Association(R) (ADA) announced the awardees of the 2026 Pathway to Stop Diabetes(R) (Pathway) Award grants. The seven new awards, totaling $11.3 million in strategic ...

In 2024, Professor Sebastian Kobold's research group at LMU University Hospital had already shown that the metabolite ...

Doctors at Boston’s Beth Israel share how CAR T cell therapy and other emerging immune therapies are delivering promising ...

BioWorld - Tuesday, February 24, 2026 Breaking News: BioWorld Science 2025 Year in Review See today's BioWorld Science Home » TRX-319 silences autoreactive B and T cells in multiple sclerosis To read ...

RNA CAR T therapy Descartes‑08 targets BCMA‑positive plasma cells and delivers year‑long symptom relief in myasthenia gravis after a brief course, signaling a new era of durable treatment.

UT Southwestern Medical Center researchers have discovered that increasing the levels of a protein called BACH2 makes engineered cancer-fighting immune cells behave more like stem cells, improving ...